Clinical Trial: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional




Official Title: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Brief Summary: This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks for up to six weeks, or a maximum of three treatments.